Navigation Links
Enobia Pharma Raises $40.1 Million Series B Financing
Date:9/11/2007

MONTREAL and QUEBEC, Sept. 11 /PRNewswire/ -- Enobia Pharma Inc, announced today that it raised $Cdn 40.1 Million in a Series B multi-tranche financing. The proceeds will be used primarily to fund the Company's novel hypophosphatasia drug development program through Phase 2 clinical trials. There is no known cure for hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone.

The financing was co-led by new investors OrbiMed Advisors LLC ("OrbiMed") of New York and CTI Life Sciences Fund of Montreal ("CTI"). The Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000, current investors in the Company, also participated in the round.

Robert Heft, PhD, President and CEO of Enobia said, "With no drug therapy available, hypophosphatasia patients and their families experience prolonged and significant suffering. We are pleased that we were able to attract such world class investors to our company at this important time in our development. We are confident that with their support, we will build on our promising preclinical results to advance the clinical development program of an enzyme replacement therapy for hypophosphatasia."

Jonathan Silverstein, General Partner of OrbiMed said, "We are delighted to be associated with this impressive team working on such a debilitating disease for which there is no cure."

Richard Meadows, Managing Partner of CTI said, "This represents an example of the type of high quality investment opportunity that exists in Quebec and that is capable of attracting the attention and significant investment from our U.S. VC colleagues."

Both Mr. Silverstein and Mr. Meadows will join the newly constituted Board, which also includes: Robert Heft, who previously served on the Board; Fredric Price, also a former Board member, and an investor in this Series B financing who was previously Chairman & CEO of BioMarin Pharmaceutical and Thomas Schuetz, MD, PhD, who was previously Vice President, Clinical Affairs, Transkaryotic Therapies Inc. Mr Silverstein has been elected Chairman of the Board of Directors.

Hypophosphatasia is caused by mutations in the gene for alkaline phosphatase, an enzyme that is essential for proper bone mineralization. The symptoms of the disorder include: growth retardation, skeletal deformities and frequent fractures. The disorder is lethal in its most severe form. Enobia is developing an enzyme replacement therapy for hypophosphatasia using a proprietary bone-targeted form of recombinant alkaline phosphatase. The Company has demonstrated promising results in a mouse model of hypophosphatasia. These results were recently presented at the Annual Meeting of the International Bone and Mineral Society (June 2007, Montreal). Additional data will be presented at the upcoming Annual Meeting of the American Society for Bone and Mineral Research (September 2007, Hawaii). Enobia anticipates initiating clinical studies in the summer 2008.

Enobia Pharma is a Montreal-based, privately held company founded in 1997. The Company is developing Enzyme Replacement Therapeutics and other compounds for the treatment of serious bone diseases.

For additional information on Enobia Pharma, please contact:

Mr. Luc Cournoyer, VP Finance

Enobia Pharma

2901 Rachel Street East, Suite 23, Montreal, Quebec, CANADA.H1W 4A4

(514) 596-2901 extension # 223

Email: luc.cournoyer@enobia.com


'/>"/>
SOURCE Enobia Pharma Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/7/2017)... Arizona (PRWEB) , ... October ... ... 15 years’ experience providing advanced instruments and applications consulting for microscopy and ... in-house expertise in application consulting, Nanoscience Analytical offers a broad range of ...
(Date:10/6/2017)... ... October 06, 2017 , ... On ... and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The ... The event is free and open to the public, but registration is required. ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
Breaking Biology News(10 mins):